UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 768

Sortiert nach

Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children

The Journal of infectious diseases, 2020-06, Vol.221 (12), p.2050-2059

2020

Volltextzugriff (PDF)

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

The Journal of infectious diseases, 2017-12, Vol.216 (11), p.1362-1370

2017

Volltextzugriff (PDF)

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Clinical infectious diseases, 2024-05, Vol.78 (5), p.1360-1368

2024

Volltextzugriff (PDF)

Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children

The Journal of infectious diseases, 2020-02, Vol.221 (4), p.534-543

2020

Volltextzugriff (PDF)

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

The Journal of infectious diseases, 2017-01, Vol.215 (1), p.24-33

2017

Volltextzugriff (PDF)

Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG

Proceedings of the National Academy of Sciences - PNAS, 2008-12, Vol.105 (52), p.20822-20827

2008

Volltextzugriff (PDF)

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

The Journal of infectious diseases, 2018-04, Vol.217 (10), p.1616-1625

2018

Volltextzugriff (PDF)

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

Science (American Association for the Advancement of Science), 2013-05, Vol.340 (6136), p.1113-1117

2013

Volltextzugriff (PDF)

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

Proceedings of the National Academy of Sciences - PNAS, 2011-06, Vol.108 (23), p.9619-9624

2011

Volltextzugriff (PDF)

Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children

The Journal of infectious diseases, 2020-06, Vol.222 (1), p.82-91

2020

Volltextzugriff (PDF)

Respiratory Syncytial Virus Load, Viral Dynamics, and Disease Severity in Previously Healthy Naturally Infected Children

The Journal of infectious diseases, 2011-10, Vol.204 (7), p.996-1002

2011

Volltextzugriff (PDF)

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy

Proceedings of the National Academy of Sciences - PNAS, 2014-04, Vol.111 (16), p.5992-5997

2014

Volltextzugriff (PDF)

Severe Human Lower Respiratory Tract Illness Caused by Respiratory Syncytial Virus and Influenza Virus Is Characterized by the Absence of Pulmonary Cytotoxic Lymphocyte Responses

The Journal of infectious diseases, 2007-04, Vol.195 (8), p.1126-1136

2007

Volltextzugriff (PDF)

Nonreplicating Vaccines Can Protect African Green Monkeys From the Memphis 37 Strain of Respiratory Syncytial Virus

The Journal of infectious diseases, 2013-07, Vol.208 (2), p.319-329

2013

Volltextzugriff (PDF)

A proof of concept for structure-based vaccine design targeting RSV in humans

Science (American Association for the Advancement of Science), 2019-08, Vol.365 (6452), p.505-509

2019

Volltextzugriff (PDF)

Innate Immune Dysfunction is Associated with Enhanced Disease Severity In Infants with Severe Respiratory Syncytial Virus Bronchiolitis

The Journal of infectious diseases, 2013-02, Vol.207 (4), p.564-573

2013

Volltextzugriff (PDF)

Young Infants Can Develop Protective Levels of Neutralizing Antibody after Infection with Respiratory Syncytial Virus

The Journal of infectious diseases, 2008-10, Vol.198 (7), p.1007-1015

2008

Volltextzugriff (PDF)

Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection

Proceedings of the National Academy of Sciences - PNAS, 2010-01, Vol.107 (1), p.320-325

2010

Volltextzugriff (PDF)

MAVS and MyD88 Are Essential for Innate Immunity but Not Cytotoxic T Lymphocyte Response against Respiratory Syncytial Virus

Proceedings of the National Academy of Sciences - PNAS, 2008-09, Vol.105 (37), p.14046-14051

2008

Volltextzugriff (PDF)

Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis

The Journal of infectious diseases, 2017-12, Vol.217 (1), p.24-34

2017

Volltextzugriff (PDF)

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

Proceedings of the National Academy of Sciences - PNAS, 2012-02, Vol.109 (8), p.3089-3094

2012

Volltextzugriff (PDF)

De novo protein design enables the precise induction of RSV-neutralizing antibodies

Science (American Association for the Advancement of Science), 2020-05, Vol.368 (6492)

2020

Volltextzugriff (PDF)

Circulating Antibody-Secreting Cells during Acute Respiratory Syncytial Virus Infection in Adults

The Journal of infectious diseases, 2010-12, Vol.202 (11), p.1659-1666

2010

Volltextzugriff (PDF)

Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States

Clinical infectious diseases, 2024-05, Vol.78 (5), p.1328-1335

2024

Volltextzugriff (PDF)

Association between Common Toll-Like Receptor 4 Mutations and Severe Respiratory Syncytial Virus Disease

The Journal of infectious diseases, 2004-06, Vol.189 (11), p.2057-2063

2004

Volltextzugriff (PDF)

1 – 25 von 768

Suche als RSS-Feed

Aktive Filter

KollektionJstor Complete Legacy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(746)
Mit Volltextzugriff
(650)

Publikationsform

Artikel
(767)
magazinearticle
(1)

Sprache

Englisch
(768)
Japanisch
(141)

Erscheinungsjahr

n.n

Thema

Science & Technology
(733)
Life Sciences & Biomedicine
(692)
Microbiology
(672)
Immunology
(663)
Infectious Diseases
(663)
Humans
(616)
Respiratory Syncytial Virus
(482)
Viruses
(428)
Human Respiratory Syncytial Virus
(343)
Infant
(324)
Infections
(314)
Biological And Medical Sciences
(278)
Female
(272)
Respiratory Syncytial Viruses
(261)
Male
(240)
Medical Sciences
(228)
Respiratory Syncytial Virus Infections
(187)
Child, Preschool
(179)
Children
(161)
Child
(155)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Live-Attenuated Respiratory Syncytial Virus Vaccine With M2-2 Deletion and With Small Hydrophobic Noncoding Region Is Highly Immunogenic in Children

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults

Safety and Immunogenicity of Bivalent RSVpreF Vaccine Coadministered With Seasonal Inactivated Influenza Vaccine in Older Adults

Live Respiratory Syncytial Virus Attenuated by M2-2 Deletion and Stabilized Temperature Sensitivity Mutation 1030s Is a Promising Vaccine Candidate in Children

A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant

Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG

Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials

Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children

Respiratory Syncytial Virus Load, Viral Dynamics, and Disease Severity in Previously Healthy Naturally Infected Children

Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy

Severe Human Lower Respiratory Tract Illness Caused by Respiratory Syncytial Virus and Influenza Virus Is Characterized by the Absence of Pulmonary Cytotoxic Lymphocyte Responses

Nonreplicating Vaccines Can Protect African Green Monkeys From the Memphis 37 Strain of Respiratory Syncytial Virus

A proof of concept for structure-based vaccine design targeting RSV in humans

Innate Immune Dysfunction is Associated with Enhanced Disease Severity In Infants with Severe Respiratory Syncytial Virus Bronchiolitis

Young Infants Can Develop Protective Levels of Neutralizing Antibody after Infection with Respiratory Syncytial Virus

Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection

MAVS and MyD88 Are Essential for Innate Immunity but Not Cytotoxic T Lymphocyte Response against Respiratory Syncytial Virus

Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

De novo protein design enables the precise induction of RSV-neutralizing antibodies

Circulating Antibody-Secreting Cells during Acute Respiratory Syncytial Virus Infection in Adults

Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory Syncytial Virus Disease for Older Adults in the United States

Association between Common Toll-Like Receptor 4 Mutations and Severe Respiratory Syncytial Virus Disease

Aktive Filter

Suchergebnisse filtern